nodes	percent_of_prediction	percent_of_DWPC	metapath
Apomorphine—HTR1D—meninx—melanoma	0.0662	0.279	CbGeAlD
Apomorphine—DRD5—eyelid—melanoma	0.0599	0.252	CbGeAlD
Apomorphine—HTR2A—hindlimb—melanoma	0.00782	0.0329	CbGeAlD
Apomorphine—HTR1B—blood vessel—melanoma	0.00776	0.0327	CbGeAlD
Apomorphine—HTR1D—blood vessel—melanoma	0.00751	0.0316	CbGeAlD
Apomorphine—CALY—head—melanoma	0.00748	0.0315	CbGeAlD
Apomorphine—HTR2A—appendage—melanoma	0.00671	0.0282	CbGeAlD
Apomorphine—CALY—lymph node—melanoma	0.00524	0.0221	CbGeAlD
Apomorphine—Pain in extremity—Vemurafenib—melanoma	0.00513	0.0296	CcSEcCtD
Apomorphine—HTR2A—endothelium—melanoma	0.00405	0.017	CbGeAlD
Apomorphine—DRD3—head—melanoma	0.00404	0.017	CbGeAlD
Apomorphine—HTR1D—eye—melanoma	0.004	0.0168	CbGeAlD
Apomorphine—DRD5—head—melanoma	0.00379	0.0159	CbGeAlD
Apomorphine—HTR2A—blood vessel—melanoma	0.00373	0.0157	CbGeAlD
Apomorphine—Injection site reaction—Carmustine—melanoma	0.00371	0.0214	CcSEcCtD
Apomorphine—HTR2B—skin of body—melanoma	0.00324	0.0136	CbGeAlD
Apomorphine—ADRA1B—head—melanoma	0.0031	0.0131	CbGeAlD
Apomorphine—Swelling—Carmustine—melanoma	0.00307	0.0177	CcSEcCtD
Apomorphine—ADRA1D—head—melanoma	0.00304	0.0128	CbGeAlD
Apomorphine—DRD2—eye—melanoma	0.00301	0.0127	CbGeAlD
Apomorphine—Back pain—Vemurafenib—melanoma	0.00299	0.0172	CcSEcCtD
Apomorphine—DRD2—retina—melanoma	0.00298	0.0126	CbGeAlD
Apomorphine—Rhinorrhoea—Docetaxel—melanoma	0.00296	0.0171	CcSEcCtD
Apomorphine—DRD1—head—melanoma	0.00289	0.0122	CbGeAlD
Apomorphine—HTR2A—neck—melanoma	0.00267	0.0112	CbGeAlD
Apomorphine—Arthralgia—Vemurafenib—melanoma	0.00263	0.0152	CcSEcCtD
Apomorphine—Dehydration—Temozolomide—melanoma	0.00244	0.0141	CcSEcCtD
Apomorphine—Pneumonia—Bleomycin—melanoma	0.00241	0.0139	CcSEcCtD
Apomorphine—Injection site reaction—Docetaxel—melanoma	0.00239	0.0138	CcSEcCtD
Apomorphine—Hypotension—Vemurafenib—melanoma	0.00235	0.0136	CcSEcCtD
Apomorphine—HTR1B—head—melanoma	0.00234	0.00987	CbGeAlD
Apomorphine—ADRA2C—mammalian vulva—melanoma	0.00232	0.00978	CbGeAlD
Apomorphine—Musculoskeletal discomfort—Vemurafenib—melanoma	0.0023	0.0133	CcSEcCtD
Apomorphine—HTR1D—head—melanoma	0.00227	0.00955	CbGeAlD
Apomorphine—HTR2C—head—melanoma	0.00225	0.00946	CbGeAlD
Apomorphine—Pneumonia—Dactinomycin—melanoma	0.00225	0.013	CcSEcCtD
Apomorphine—Sweating increased—Temozolomide—melanoma	0.00221	0.0127	CcSEcCtD
Apomorphine—Fatigue—Vemurafenib—melanoma	0.00217	0.0125	CcSEcCtD
Apomorphine—Constipation—Vemurafenib—melanoma	0.00215	0.0124	CcSEcCtD
Apomorphine—HTR2B—head—melanoma	0.00211	0.00889	CbGeAlD
Apomorphine—Pneumonia—Carmustine—melanoma	0.0021	0.0121	CcSEcCtD
Apomorphine—Urinary tract infection—Carmustine—melanoma	0.00203	0.0117	CcSEcCtD
Apomorphine—Pneumonia—Temozolomide—melanoma	0.00203	0.0117	CcSEcCtD
Apomorphine—Flushing—Bleomycin—melanoma	0.00199	0.0115	CcSEcCtD
Apomorphine—HTR2A—eye—melanoma	0.00199	0.00836	CbGeAlD
Apomorphine—Swelling—Docetaxel—melanoma	0.00198	0.0114	CcSEcCtD
Apomorphine—HTR2A—retina—melanoma	0.00197	0.00829	CbGeAlD
Apomorphine—Urinary tract infection—Temozolomide—melanoma	0.00196	0.0113	CcSEcCtD
Apomorphine—Cardiac failure congestive—Docetaxel—melanoma	0.00192	0.0111	CcSEcCtD
Apomorphine—HTR1A—head—melanoma	0.00189	0.00796	CbGeAlD
Apomorphine—Hallucination—Carmustine—melanoma	0.00187	0.0108	CcSEcCtD
Apomorphine—Flushing—Dactinomycin—melanoma	0.00186	0.0107	CcSEcCtD
Apomorphine—ADRA2A—mammalian vulva—melanoma	0.00185	0.0078	CbGeAlD
Apomorphine—Asthenia—Vemurafenib—melanoma	0.00181	0.0104	CcSEcCtD
Apomorphine—Hallucination—Temozolomide—melanoma	0.0018	0.0104	CcSEcCtD
Apomorphine—Pruritus—Vemurafenib—melanoma	0.00178	0.0103	CcSEcCtD
Apomorphine—Pain in extremity—Docetaxel—melanoma	0.00174	0.0101	CcSEcCtD
Apomorphine—Flushing—Carmustine—melanoma	0.00174	0.0101	CcSEcCtD
Apomorphine—Diarrhoea—Vemurafenib—melanoma	0.00172	0.00995	CcSEcCtD
Apomorphine—DRD2—head—melanoma	0.00171	0.0072	CbGeAlD
Apomorphine—Flushing—Temozolomide—melanoma	0.00168	0.00971	CcSEcCtD
Apomorphine—Dizziness—Vemurafenib—melanoma	0.00167	0.00962	CcSEcCtD
Apomorphine—ADRA2C—head—melanoma	0.00166	0.007	CbGeAlD
Apomorphine—Mental disorder—Carmustine—melanoma	0.00164	0.00949	CcSEcCtD
Apomorphine—Dehydration—Docetaxel—melanoma	0.00162	0.00936	CcSEcCtD
Apomorphine—Vomiting—Vemurafenib—melanoma	0.0016	0.00925	CcSEcCtD
Apomorphine—Chest pain—Bleomycin—melanoma	0.00159	0.00919	CcSEcCtD
Apomorphine—Orthostatic hypotension—Docetaxel—melanoma	0.00159	0.00919	CcSEcCtD
Apomorphine—Mental disorder—Temozolomide—melanoma	0.00159	0.00917	CcSEcCtD
Apomorphine—Back pain—Carmustine—melanoma	0.00158	0.00912	CcSEcCtD
Apomorphine—Headache—Vemurafenib—melanoma	0.00158	0.00911	CcSEcCtD
Apomorphine—Nasopharyngitis—Docetaxel—melanoma	0.00156	0.009	CcSEcCtD
Apomorphine—Confusional state—Bleomycin—melanoma	0.00154	0.00889	CcSEcCtD
Apomorphine—Oedema—Bleomycin—melanoma	0.00153	0.00881	CcSEcCtD
Apomorphine—Back pain—Temozolomide—melanoma	0.00153	0.00881	CcSEcCtD
Apomorphine—Nausea—Vemurafenib—melanoma	0.0015	0.00864	CcSEcCtD
Apomorphine—HTR2B—lymph node—melanoma	0.00148	0.00622	CbGeAlD
Apomorphine—Angina pectoris—Docetaxel—melanoma	0.00147	0.00847	CcSEcCtD
Apomorphine—Hypotension—Bleomycin—melanoma	0.00143	0.00824	CcSEcCtD
Apomorphine—Oedema—Dactinomycin—melanoma	0.00142	0.00822	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Bleomycin—melanoma	0.00139	0.00803	CcSEcCtD
Apomorphine—Chest pain—Carmustine—melanoma	0.00139	0.00803	CcSEcCtD
Apomorphine—Anxiety—Carmustine—melanoma	0.00139	0.008	CcSEcCtD
Apomorphine—Dyspnoea—Bleomycin—melanoma	0.00136	0.00786	CcSEcCtD
Apomorphine—Pneumonia—Docetaxel—melanoma	0.00135	0.0078	CcSEcCtD
Apomorphine—Confusional state—Carmustine—melanoma	0.00134	0.00776	CcSEcCtD
Apomorphine—Arthralgia—Temozolomide—melanoma	0.00134	0.00776	CcSEcCtD
Apomorphine—Anxiety—Temozolomide—melanoma	0.00134	0.00773	CcSEcCtD
Apomorphine—Oedema—Carmustine—melanoma	0.00133	0.00769	CcSEcCtD
Apomorphine—ADRA2A—head—melanoma	0.00133	0.00558	CbGeAlD
Apomorphine—Confusional state—Temozolomide—melanoma	0.0013	0.0075	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Dactinomycin—melanoma	0.0013	0.00749	CcSEcCtD
Apomorphine—Oedema—Temozolomide—melanoma	0.00129	0.00744	CcSEcCtD
Apomorphine—Feeling abnormal—Bleomycin—melanoma	0.00126	0.00726	CcSEcCtD
Apomorphine—Hypotension—Carmustine—melanoma	0.00125	0.00719	CcSEcCtD
Apomorphine—Hyperhidrosis—Temozolomide—melanoma	0.00125	0.00719	CcSEcCtD
Apomorphine—Fatigue—Dactinomycin—melanoma	0.00123	0.00709	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Carmustine—melanoma	0.00121	0.00701	CcSEcCtD
Apomorphine—Insomnia—Carmustine—melanoma	0.00121	0.00696	CcSEcCtD
Apomorphine—Dyspnoea—Carmustine—melanoma	0.00119	0.00686	CcSEcCtD
Apomorphine—Somnolence—Carmustine—melanoma	0.00118	0.00684	CcSEcCtD
Apomorphine—Feeling abnormal—Dactinomycin—melanoma	0.00117	0.00677	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Temozolomide—melanoma	0.00117	0.00677	CcSEcCtD
Apomorphine—Insomnia—Temozolomide—melanoma	0.00116	0.00672	CcSEcCtD
Apomorphine—ADRA2C—lymph node—melanoma	0.00116	0.0049	CbGeAlD
Apomorphine—Dyspnoea—Temozolomide—melanoma	0.00115	0.00663	CcSEcCtD
Apomorphine—Somnolence—Temozolomide—melanoma	0.00114	0.00661	CcSEcCtD
Apomorphine—Constipation—Carmustine—melanoma	0.00114	0.00658	CcSEcCtD
Apomorphine—HTR2A—head—melanoma	0.00113	0.00475	CbGeAlD
Apomorphine—Flushing—Docetaxel—melanoma	0.00112	0.00646	CcSEcCtD
Apomorphine—Fatigue—Temozolomide—melanoma	0.00111	0.00641	CcSEcCtD
Apomorphine—Constipation—Temozolomide—melanoma	0.0011	0.00636	CcSEcCtD
Apomorphine—Feeling abnormal—Carmustine—melanoma	0.0011	0.00634	CcSEcCtD
Apomorphine—Asthenia—Bleomycin—melanoma	0.0011	0.00632	CcSEcCtD
Apomorphine—Pruritus—Bleomycin—melanoma	0.00108	0.00624	CcSEcCtD
Apomorphine—Feeling abnormal—Temozolomide—melanoma	0.00106	0.00613	CcSEcCtD
Apomorphine—Mental disorder—Docetaxel—melanoma	0.00106	0.0061	CcSEcCtD
Apomorphine—Asthenia—Dactinomycin—melanoma	0.00102	0.0059	CcSEcCtD
Apomorphine—Back pain—Docetaxel—melanoma	0.00102	0.00586	CcSEcCtD
Apomorphine—Diarrhoea—Dactinomycin—melanoma	0.000974	0.00562	CcSEcCtD
Apomorphine—Vomiting—Bleomycin—melanoma	0.000971	0.0056	CcSEcCtD
Apomorphine—Asthenia—Carmustine—melanoma	0.000956	0.00552	CcSEcCtD
Apomorphine—Syncope—Docetaxel—melanoma	0.000941	0.00543	CcSEcCtD
Apomorphine—ADRA2A—lymph node—melanoma	0.000929	0.00391	CbGeAlD
Apomorphine—Asthenia—Temozolomide—melanoma	0.000924	0.00533	CcSEcCtD
Apomorphine—Loss of consciousness—Docetaxel—melanoma	0.000922	0.00532	CcSEcCtD
Apomorphine—Diarrhoea—Carmustine—melanoma	0.000912	0.00526	CcSEcCtD
Apomorphine—Pruritus—Temozolomide—melanoma	0.000911	0.00526	CcSEcCtD
Apomorphine—Nausea—Bleomycin—melanoma	0.000907	0.00524	CcSEcCtD
Apomorphine—Vomiting—Dactinomycin—melanoma	0.000905	0.00523	CcSEcCtD
Apomorphine—Arthralgia—Docetaxel—melanoma	0.000893	0.00516	CcSEcCtD
Apomorphine—Chest pain—Docetaxel—melanoma	0.000893	0.00516	CcSEcCtD
Apomorphine—Dizziness—Carmustine—melanoma	0.000881	0.00509	CcSEcCtD
Apomorphine—Diarrhoea—Temozolomide—melanoma	0.000881	0.00509	CcSEcCtD
Apomorphine—Confusional state—Docetaxel—melanoma	0.000864	0.00499	CcSEcCtD
Apomorphine—Oedema—Docetaxel—melanoma	0.000856	0.00494	CcSEcCtD
Apomorphine—Dizziness—Temozolomide—melanoma	0.000852	0.00492	CcSEcCtD
Apomorphine—Vomiting—Carmustine—melanoma	0.000847	0.00489	CcSEcCtD
Apomorphine—Nausea—Dactinomycin—melanoma	0.000846	0.00488	CcSEcCtD
Apomorphine—Shock—Docetaxel—melanoma	0.000843	0.00486	CcSEcCtD
Apomorphine—Headache—Carmustine—melanoma	0.000835	0.00482	CcSEcCtD
Apomorphine—Vomiting—Temozolomide—melanoma	0.000819	0.00473	CcSEcCtD
Apomorphine—Headache—Temozolomide—melanoma	0.000807	0.00466	CcSEcCtD
Apomorphine—Hypotension—Docetaxel—melanoma	0.0008	0.00462	CcSEcCtD
Apomorphine—Nausea—Carmustine—melanoma	0.000792	0.00457	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Docetaxel—melanoma	0.00078	0.0045	CcSEcCtD
Apomorphine—Insomnia—Docetaxel—melanoma	0.000775	0.00447	CcSEcCtD
Apomorphine—Nausea—Temozolomide—melanoma	0.000765	0.00442	CcSEcCtD
Apomorphine—Dyspnoea—Docetaxel—melanoma	0.000764	0.00441	CcSEcCtD
Apomorphine—Somnolence—Docetaxel—melanoma	0.000761	0.0044	CcSEcCtD
Apomorphine—Fatigue—Docetaxel—melanoma	0.000738	0.00426	CcSEcCtD
Apomorphine—Constipation—Docetaxel—melanoma	0.000732	0.00423	CcSEcCtD
Apomorphine—Feeling abnormal—Docetaxel—melanoma	0.000706	0.00407	CcSEcCtD
Apomorphine—Asthenia—Docetaxel—melanoma	0.000614	0.00355	CcSEcCtD
Apomorphine—Pruritus—Docetaxel—melanoma	0.000606	0.0035	CcSEcCtD
Apomorphine—Diarrhoea—Docetaxel—melanoma	0.000586	0.00338	CcSEcCtD
Apomorphine—Dizziness—Docetaxel—melanoma	0.000566	0.00327	CcSEcCtD
Apomorphine—Vomiting—Docetaxel—melanoma	0.000545	0.00314	CcSEcCtD
Apomorphine—Headache—Docetaxel—melanoma	0.000537	0.0031	CcSEcCtD
Apomorphine—Nausea—Docetaxel—melanoma	0.000509	0.00294	CcSEcCtD
Apomorphine—HTR2B—Signaling Pathways—MYC—melanoma	1.69e-05	2.88e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—NRAS—melanoma	1.69e-05	2.87e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—NRAS—melanoma	1.69e-05	2.87e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling by GPCR—IL6—melanoma	1.69e-05	2.87e-05	CbGpPWpGaD
Apomorphine—ADRA1B—GPCR downstream signaling—AKT1—melanoma	1.69e-05	2.87e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—KRAS—melanoma	1.69e-05	2.87e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—CTNNB1—melanoma	1.69e-05	2.86e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—PIK3CB—melanoma	1.68e-05	2.85e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—CASP3—melanoma	1.68e-05	2.84e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—ERBB2—melanoma	1.67e-05	2.84e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—IL2—melanoma	1.67e-05	2.84e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling by GPCR—AKT1—melanoma	1.67e-05	2.84e-05	CbGpPWpGaD
Apomorphine—DRD5—Signaling Pathways—AKT1—melanoma	1.67e-05	2.83e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—KRAS—melanoma	1.67e-05	2.83e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling by GPCR—IL6—melanoma	1.67e-05	2.83e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—MMP9—melanoma	1.66e-05	2.82e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—CCND1—melanoma	1.66e-05	2.81e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—MAPK1—melanoma	1.66e-05	2.81e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—EGFR—melanoma	1.66e-05	2.81e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—CDKN1A—melanoma	1.66e-05	2.81e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—MMP9—melanoma	1.65e-05	2.81e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—PTEN—melanoma	1.65e-05	2.81e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—PIK3CB—melanoma	1.65e-05	2.81e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—FGF2—melanoma	1.65e-05	2.8e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—CDKN1A—melanoma	1.65e-05	2.8e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—NFKB1—melanoma	1.65e-05	2.79e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—PTEN—melanoma	1.64e-05	2.79e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—MAPK3—melanoma	1.64e-05	2.79e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—CTNNB1—melanoma	1.64e-05	2.79e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—KRAS—melanoma	1.64e-05	2.78e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—NFKB1—melanoma	1.64e-05	2.78e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—CCND1—melanoma	1.63e-05	2.77e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—MAPK3—melanoma	1.62e-05	2.75e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—MAPK3—melanoma	1.62e-05	2.75e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—CTNNB1—melanoma	1.62e-05	2.74e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CXCL8—melanoma	1.61e-05	2.74e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling by GPCR—AKT1—melanoma	1.61e-05	2.74e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—MMP9—melanoma	1.61e-05	2.73e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling by GPCR—AKT1—melanoma	1.6e-05	2.72e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling by GPCR—HRAS—melanoma	1.6e-05	2.72e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—CDKN1A—melanoma	1.6e-05	2.72e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—PTEN—melanoma	1.6e-05	2.72e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—MYC—melanoma	1.6e-05	2.71e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—NFKB1—melanoma	1.59e-05	2.7e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CXCL8—melanoma	1.59e-05	2.7e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—MMP9—melanoma	1.58e-05	2.69e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling by GPCR—HRAS—melanoma	1.58e-05	2.68e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—CDKN1A—melanoma	1.58e-05	2.68e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—MYC—melanoma	1.58e-05	2.68e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CDKN1B—melanoma	1.58e-05	2.68e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—MYC—melanoma	1.58e-05	2.68e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—PTEN—melanoma	1.57e-05	2.67e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—NFKB1—melanoma	1.57e-05	2.66e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—KRAS—melanoma	1.57e-05	2.66e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—PIK3CA—melanoma	1.56e-05	2.65e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—MAPK1—melanoma	1.56e-05	2.65e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—EGFR—melanoma	1.56e-05	2.65e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling by GPCR—AKT1—melanoma	1.56e-05	2.65e-05	CbGpPWpGaD
Apomorphine—DRD2—GPCR downstream signaling—AKT1—melanoma	1.56e-05	2.65e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—PTEN—melanoma	1.55e-05	2.64e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—PIK3CA—melanoma	1.55e-05	2.63e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CDKN1B—melanoma	1.55e-05	2.63e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—VEGFA—melanoma	1.55e-05	2.63e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—MDM2—melanoma	1.55e-05	2.62e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CASP3—melanoma	1.55e-05	2.62e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—IL2—melanoma	1.54e-05	2.62e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—MAPK1—melanoma	1.54e-05	2.62e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—MAPK1—melanoma	1.54e-05	2.62e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—EGFR—melanoma	1.54e-05	2.62e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—EGFR—melanoma	1.54e-05	2.62e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling by GPCR—AKT1—melanoma	1.54e-05	2.61e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling by GPCR—IL6—melanoma	1.54e-05	2.61e-05	CbGpPWpGaD
Apomorphine—HTR2A—GPCR downstream signaling—AKT1—melanoma	1.53e-05	2.6e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—STAT3—melanoma	1.53e-05	2.6e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—PIK3CA—melanoma	1.53e-05	2.6e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—NRAS—melanoma	1.53e-05	2.59e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—ERBB2—melanoma	1.52e-05	2.59e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CASP3—melanoma	1.52e-05	2.58e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—IL2—melanoma	1.52e-05	2.58e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—TP53—melanoma	1.51e-05	2.57e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling by GPCR—IL6—melanoma	1.51e-05	2.56e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—PIK3CA—melanoma	1.51e-05	2.56e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CCND1—melanoma	1.5e-05	2.55e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—PIK3CB—melanoma	1.5e-05	2.55e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—VEGFA—melanoma	1.49e-05	2.53e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CTNNB1—melanoma	1.49e-05	2.53e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—VEGFA—melanoma	1.49e-05	2.52e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—TP53—melanoma	1.48e-05	2.51e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CCND1—melanoma	1.48e-05	2.51e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—STAT3—melanoma	1.48e-05	2.51e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—KRAS—melanoma	1.48e-05	2.51e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—NRAS—melanoma	1.48e-05	2.5e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—STAT3—melanoma	1.47e-05	2.5e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—NRAS—melanoma	1.47e-05	2.49e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CTNNB1—melanoma	1.47e-05	2.49e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—MAPK3—melanoma	1.46e-05	2.48e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—MMP9—melanoma	1.46e-05	2.48e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—TP53—melanoma	1.46e-05	2.47e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—KRAS—melanoma	1.46e-05	2.47e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—KRAS—melanoma	1.46e-05	2.47e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CDKN1A—melanoma	1.45e-05	2.47e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—PTEN—melanoma	1.45e-05	2.46e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—HRAS—melanoma	1.45e-05	2.46e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CXCL8—melanoma	1.45e-05	2.45e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—VEGFA—melanoma	1.44e-05	2.45e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—NFKB1—melanoma	1.44e-05	2.45e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—PIK3CA—melanoma	1.44e-05	2.44e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—MMP9—melanoma	1.44e-05	2.44e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—HRAS—melanoma	1.44e-05	2.44e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CDKN1A—melanoma	1.43e-05	2.43e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—STAT3—melanoma	1.43e-05	2.43e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—PTEN—melanoma	1.43e-05	2.42e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—NRAS—melanoma	1.43e-05	2.42e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—MYC—melanoma	1.42e-05	2.42e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—VEGFA—melanoma	1.42e-05	2.41e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—NFKB1—melanoma	1.42e-05	2.41e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—HRAS—melanoma	1.42e-05	2.4e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling by GPCR—AKT1—melanoma	1.42e-05	2.4e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—MAPK3—melanoma	1.41e-05	2.4e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CDKN1B—melanoma	1.41e-05	2.4e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—STAT3—melanoma	1.41e-05	2.39e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—MAPK3—melanoma	1.41e-05	2.39e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—NRAS—melanoma	1.4e-05	2.38e-05	CbGpPWpGaD
Apomorphine—ADRA2A—GPCR downstream signaling—AKT1—melanoma	1.4e-05	2.37e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—HRAS—melanoma	1.39e-05	2.37e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling by GPCR—AKT1—melanoma	1.39e-05	2.36e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—MAPK1—melanoma	1.39e-05	2.36e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—EGFR—melanoma	1.39e-05	2.36e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—TP53—melanoma	1.39e-05	2.36e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—IL6—melanoma	1.38e-05	2.35e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CASP3—melanoma	1.38e-05	2.35e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—IL2—melanoma	1.38e-05	2.34e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—IL6—melanoma	1.37e-05	2.33e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—MYC—melanoma	1.37e-05	2.33e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—MAPK3—melanoma	1.37e-05	2.32e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—MYC—melanoma	1.37e-05	2.32e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—PIK3CA—melanoma	1.36e-05	2.3e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—IL6—melanoma	1.36e-05	2.3e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Metabolism—PIK3CA—melanoma	1.35e-05	2.29e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CCND1—melanoma	1.35e-05	2.29e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—MAPK3—melanoma	1.35e-05	2.28e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—MAPK1—melanoma	1.34e-05	2.28e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—EGFR—melanoma	1.34e-05	2.28e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—PIK3CA—melanoma	1.34e-05	2.27e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—PIK3CA—melanoma	1.34e-05	2.27e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—MAPK1—melanoma	1.34e-05	2.27e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—EGFR—melanoma	1.34e-05	2.27e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—IL6—melanoma	1.33e-05	2.26e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CTNNB1—melanoma	1.33e-05	2.26e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—HRAS—melanoma	1.33e-05	2.26e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—MYC—melanoma	1.33e-05	2.26e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—KRAS—melanoma	1.32e-05	2.23e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—TP53—melanoma	1.31e-05	2.23e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—VEGFA—melanoma	1.31e-05	2.23e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—MYC—melanoma	1.31e-05	2.22e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—MMP9—melanoma	1.31e-05	2.22e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CDKN1A—melanoma	1.3e-05	2.21e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—MAPK1—melanoma	1.3e-05	2.21e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—EGFR—melanoma	1.3e-05	2.21e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—PTEN—melanoma	1.3e-05	2.21e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—STAT3—melanoma	1.3e-05	2.2e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—NRAS—melanoma	1.3e-05	2.2e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—TP53—melanoma	1.29e-05	2.2e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—TP53—melanoma	1.29e-05	2.2e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—NFKB1—melanoma	1.29e-05	2.19e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—VEGFA—melanoma	1.29e-05	2.19e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—MAPK1—melanoma	1.28e-05	2.17e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—EGFR—melanoma	1.28e-05	2.17e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—STAT3—melanoma	1.28e-05	2.17e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—AKT1—melanoma	1.28e-05	2.17e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—NRAS—melanoma	1.27e-05	2.16e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—IL6—melanoma	1.27e-05	2.16e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—KRAS—melanoma	1.27e-05	2.15e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—AKT1—melanoma	1.27e-05	2.15e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—KRAS—melanoma	1.26e-05	2.14e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—HRAS—melanoma	1.25e-05	2.13e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—AKT1—melanoma	1.25e-05	2.12e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—MAPK3—melanoma	1.24e-05	2.11e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—HRAS—melanoma	1.24e-05	2.1e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—HRAS—melanoma	1.24e-05	2.1e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—AKT1—melanoma	1.23e-05	2.09e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—KRAS—melanoma	1.23e-05	2.08e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—MAPK3—melanoma	1.22e-05	2.07e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—KRAS—melanoma	1.21e-05	2.05e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—PIK3CA—melanoma	1.21e-05	2.05e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—MYC—melanoma	1.21e-05	2.05e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—IL6—melanoma	1.2e-05	2.04e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—MYC—melanoma	1.19e-05	2.01e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—IL6—melanoma	1.19e-05	2.01e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—IL6—melanoma	1.19e-05	2.01e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—MAPK1—melanoma	1.18e-05	2e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—EGFR—melanoma	1.18e-05	2e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—AKT1—melanoma	1.17e-05	1.99e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—VEGFA—melanoma	1.17e-05	1.99e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—TP53—melanoma	1.17e-05	1.98e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—PIK3CA—melanoma	1.17e-05	1.98e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—STAT3—melanoma	1.16e-05	1.97e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—MAPK1—melanoma	1.16e-05	1.97e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—EGFR—melanoma	1.16e-05	1.97e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—PIK3CA—melanoma	1.16e-05	1.97e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—NRAS—melanoma	1.16e-05	1.97e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—PIK3CA—melanoma	1.13e-05	1.92e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—TP53—melanoma	1.13e-05	1.92e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—TP53—melanoma	1.12e-05	1.91e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—HRAS—melanoma	1.12e-05	1.9e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—KRAS—melanoma	1.11e-05	1.89e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—PIK3CA—melanoma	1.11e-05	1.89e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—MAPK3—melanoma	1.11e-05	1.88e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—AKT1—melanoma	1.11e-05	1.88e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Metabolism—AKT1—melanoma	1.1e-05	1.87e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—KRAS—melanoma	1.1e-05	1.86e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—PIK3CA—melanoma	1.1e-05	1.86e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—AKT1—melanoma	1.09e-05	1.86e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—AKT1—melanoma	1.09e-05	1.86e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—TP53—melanoma	1.09e-05	1.85e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—MYC—melanoma	1.08e-05	1.83e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—HRAS—melanoma	1.08e-05	1.83e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—TP53—melanoma	1.07e-05	1.82e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—HRAS—melanoma	1.07e-05	1.82e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—IL6—melanoma	1.07e-05	1.82e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—MAPK1—melanoma	1.06e-05	1.79e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—EGFR—melanoma	1.06e-05	1.79e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—HRAS—melanoma	1.04e-05	1.77e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—IL6—melanoma	1.03e-05	1.75e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—HRAS—melanoma	1.03e-05	1.74e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—IL6—melanoma	1.03e-05	1.74e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—PIK3CA—melanoma	1.02e-05	1.74e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—PIK3CA—melanoma	1.01e-05	1.71e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—IL6—melanoma	9.99e-06	1.7e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—KRAS—melanoma	9.98e-06	1.69e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—TP53—melanoma	9.91e-06	1.68e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—AKT1—melanoma	9.87e-06	1.68e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—IL6—melanoma	9.84e-06	1.67e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—TP53—melanoma	9.75e-06	1.65e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—AKT1—melanoma	9.53e-06	1.62e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—AKT1—melanoma	9.48e-06	1.61e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—HRAS—melanoma	9.47e-06	1.61e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—HRAS—melanoma	9.32e-06	1.58e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—AKT1—melanoma	9.22e-06	1.56e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—PIK3CA—melanoma	9.17e-06	1.56e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—AKT1—melanoma	9.07e-06	1.54e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—IL6—melanoma	9.07e-06	1.54e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—AKT1—melanoma	8.96e-06	1.52e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—IL6—melanoma	8.92e-06	1.51e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—TP53—melanoma	8.87e-06	1.51e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—HRAS—melanoma	8.48e-06	1.44e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—AKT1—melanoma	8.37e-06	1.42e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—AKT1—melanoma	8.23e-06	1.4e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—IL6—melanoma	8.12e-06	1.38e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—AKT1—melanoma	7.49e-06	1.27e-05	CbGpPWpGaD
